In a phase 2 trial, a gene therapy reduced angioedema attacks, which could significantly change the quality of life for ...

Background: Kallikrein-1 is a serine protease expressed in multiple tissues including the kidney, where it is secreted into the urine. Low urinary kallikrein levels are associated with essential ...

Poseida Therapeutics’ gene therapy for hereditary angioedema (HAE) reduced kallikrein protein activity in a mouse model of the disease and edited a gene in the livers of nonhuman primates ...

Opens in a new tab or window A single dose of the CRISPR-based gene-editing therapy NTLA-2002 reduced angioedema attacks and led to sustained reduction in total plasma kallikrein protein levels ...

Our lead program, navenibart (STAR-0215), is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Our second program, STAR-0310, is ...

The lower 25mg dose corresponded to a 55% reduction in plasma kallikrein, while the 50mg dose reduced levels by 86%. The dose ...

BioCryst Pharmaceuticals ( (BCRX) ) has released its Q3 earnings. Here is a breakdown of the information BioCryst Pharmaceuticals presented to ...

Press Release Distributed by ABNewswire.com To view the original version on ABNewswire visit: Hereditary Angioedema Market Size in the 7MM is expected to Grow by 2034, estimates DelveInsight ...

Intellia Therapeutics fell 20.5% the day after it reported Phase 2 test results for a promising treatment. Explore more ...

NTLA-2002 targets the gene encoding kallikrein B1 (KLKB1). A single dose of NTLA-2002 may provide lifelong control of angioedema attacks. In this phase 2 portion of a phase 1–2 trial ...

KalVista Pharmaceuticals (KALV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...

The FDA has accepted the NDA for donidalorsen for the prophylactic treatment of hereditary angioedema in patients aged 12 years and older.